Not investment advice. Educational platform. See Disclaimer.
NYSE: JNJ
Johnson & Johnson
Healthcare | Drug Manufacturers - General
$273.14as of 2026-08-26 08:02 UTC
Market Cap$663.6B
EPS (TTM)$11.03
Johnson & Johnson (NYSE: JNJ) is a $663.6B drug manufacturers - general company trading at $273.14 — 24.8× trailing earnings, yielding 1.87%. Figures from SEC EDGAR and market feeds; updated 2026-08-26 08:02 UTC.
52-Week Range
Low $220.37High $276.47
What Johnson & Johnson does
Johnson & Johnson is a holding company with approximately 138,200 employees worldwide that researches, develops, manufactures, and sells healthcare products. The company operates through two business segments: Innovative Medicine and MedTech, conducting business in virtually all countries. The Innovative Medicine segment focuses on prescription medications across therapeutic areas including oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular conditions, distributing products through retailers, wholesalers, distributors, hospitals, and healthcare…
Johnson & Johnson is a holding company with approximately 138,200 employees worldwide that researches, develops, manufactures, and sells healthcare products.
What is JNJ's valuation?
JNJ trades at $273.14, 24.76× trailing earnings, as of 2026-08-26. It carries a 1.87% dividend yield.
When did JNJ last file with the SEC?
Johnson & Johnson's most recent SEC filing on record is a 8-K filed 2026-08-04. All filings link to their SEC EDGAR originals above.
Where does this data come from?
SEC EDGAR filings and public market data feeds, fetched 2026-08-26 08:02 UTC. This page is also available as JSON at /api/data?ticker=JNJ and is emitted with FAQPage structured data for machine reading.
For you
Charts, 10-year financials, peer comparison, screening and portfolio tracking for JNJ and 5,000+ tickers.
